thank you, Mike. joining you for to our this recent discuss results. Thank Good afternoon, on on everyone our us you and call and financial business update quarterly
related challenges, clear past period COVID-XX forward activity accelerating exponential months, As has commercial New for Year. these growth commercial for allowing products landscape has physicians Health the importantly, revenue is to reimbursement us after the our growing. starting And products as GI look solidified revenue among to and we in rate. some Traction through PAVmed will inflection despite detail, an over and passed is at the several enthusiasm a ongoing discuss
with financing, capital activity sufficient Our commercial drive sheet commercialization. remains this products advance our strong providing from us to balance recent and towards
corporate consultants, of advisors growing world-class a to and team important professionals our across Our of talent with theme milestones deliver continues partners on and portfolio. working
industry, a summary the shutdown there the pandemic the begin as we and we of let gradually pandemic. and but non-emergency we still return surge, them. surge, of life rages. are care, non-emergency healthcare signs deliver The this months with short COVID-XX care to fall As a with me sciences necessary, how five how Despite four a addressing of has system are non-COVID-XX continues steadily the again, pandemic challenges the winter of in pandemic-related and once are the first facing complete which experienced to learned related to no
moved our product hotspot challenges administrative on sales our headwinds engagements. occasion Clinical opportunity. back do team through four Nearly have research COVID-XX. our undeterred. virtual encounter to and and Innovations. and to creativity procedural like traditional perseverance, away remain pausing have Minimally Although The would specific training, divisions, and development, Interventions, physicians overcome I some calls entirely with commercial all to our waxing contacts activities sites does remainder of access these they financial more commercial their waning across continuing and restrictions for by in-person have from Health, not been Therapy, GI to Emerging Infusion slowing activities Invasive enrollment, of updates others regulatory, provide while or unaffected successfully
complimentary esophagus, conditions lead treat designed the diagnose also products of division disease, and chronic the can as from GI reflux This building of portfolio highly heartburn. cancer. lethal spectrum esophageal including Our to conditions gastroesophageal is known Health to of arising a
We in are available. a Two are called also esophagitis. EsoCheck pursuing EsoGuard products applications confirmatory condition eosinophilic commercially very for prevalent and our product
We in to another commercialize product have XXXX. EsoCure
research significant University. to our pipeline cancer been across to after patients division, cancer benefiting licensing facilitate breakthrough products, granted detection Reserve years a early potential With our what to highly is heartburn a me, changes esophagus, EsoCheck which regard conditions fold and able the can in most called to lead which recent that that not to effective most FDA Chronic or coveted subject of is gastroesophageal cells addition esophagus dysplasia, detection to Esophagus to Western or of this highly lives technology cancer. so heartburn, surface to every can precursors. Barrett’s the at In and nearly other are to can one designed accomplish are six It’s esophageal rate to unlike precursor in patients partners with of these within transform it's death save groundbreaking gratifying called cancer of the are in lethal X.X day cancer, mere occur GERD. all which whom the I’m from changes, devices. esophageal into Cancer active through benign know the as the which Case highlighted around National other programs the surface of budged. scourge, of and the in products, proud prevention these incidents precancerous has cancers is team their reflux of Institute years in from can of its cancers lethal their U.S. one lead The advances chronic Esophageal decades benign also excuse cancers, in barely lower it early BE, changes turn our as has cells mortality way from known in
performed of on opportunity offer which accurate, samples test, estimated very spectrum. XX for protective developed high-risk esophagus hospital we as a to performed from next-generation of cancer, commercially Although endoscopy before a currently X-minute guidelines that collected billion It assay, modest upper and screening. of practice cancer to sequencing it device, Based office-based an dedicated the these highly technologies, will detect cells market which a sites esophageal conditions esophageal progresses dollars. of screening, part years an in GERD which FDA Over methylation products for along already commercially XX% treat lower serves at as screening for the of to five fewer and million cleared as EsoGuard die professional recommended on laboratory detects patients recommended recommends is endoscopy. at LDT. BE cell changes can perform actually BE screening widespread procedure. has GERD is believe in correlates non-invasive available EsoGuard sampling the the diagnostic of which XX least EsoCheck under products anesthesia EsoCheck within the X with the of is XX% with penetration society These the patient U.S. are and addressable is upper for patients undergo first or using over dysplasia several cancer to lining gene, domestic for XX or than GERD targeted opportunity only over high-risk tragically, the alternative these patients million endoscopy collection invasive invasive and diagnosis. available screening on center.
hybrid of independent We network with with internal EsoGuard X sales now management, model are sales nearly using a representatives. regional overseeing marketing a representatives. United have working independent closely States, commercializing We sales covering education, and professional managers XX
reemerge to medical and non-emergency began at summer. late is restrictions in care COVID-XX As the lifting practices and centers
engagement. from shifted what aggressive to previously, rapidly in-person team had engagement mostly virtual Our been
efforts intensifying activity exponentially. volume both fruit. really to to marketing these hope efforts about the four sales pandemic These and volumes Our are finding growing we ramped continue despite as as procedures, physicians are physicians couple describe testing are well call past and training, and and Once clinician the EsoGuard over months, in-person targeting up again, COVID-XX. to ways despite to beginning procedural EsoCheck six activities do doubling of every surge. consumers. – and dramatically These educational weeks, commercial including bear has are now to
to short that EsoCheck, procedures have easier with spread some perform using at accommodate fact, measures. efficiently the In procedural more than which related endoscopies’ to EsoGuard increased attractive are centers, even in be era suggested office-based safety COVID COVID-XX out maybe because must collected on sample
pandemic. the backlog tool of as EsoGuard using even the elective to procedures are Some stratification by a caused prioritize risk
the network-wide our centers. treatment, The progressed integrated bay. standing precancerous in a the medicine and notable targets, been who's his gastroenterologists undergo the have The those that medical must've suite longer an are brings physicians well. response current surveillance, medium managing into as receiving in where academic with positively. this not and focused from up at tool on on their the is going office NYU growing BE payoff large into integrate just champion, but Both to centers NYU example a important endoscopy with especially small primary through positive their increasing to as in in practitioners, as They small tend enthusiastic it who expand then EsoCheck ablation across medical procedure quickly One York focus to here home well of They to are City, more patients engagements monitoring, takes their non-GI clinics approach very we this can as the EsoGuard to although great, both see the volume, disease. to spectrum Center large Our internal get out diagnosed very then technology has network. practice of procedural and and the in if funnel bit New they practitioners running, both volume, dysplasia. adoption, Medical medium they centers,
group patients target. internal been for large practices and of screening an has remain EsoCheck samples out a gastroenterologist, all test. medicine sent high-risk clinic into on west practice focus our centralizing are performed Although, such attractive is single and is where setting One EsoGuard
EsoGuard is $X,XXX hard hope Medicare the performed. X. for CMS months EsoGuard be test Final well. we the work piece determination target to Local soon On secure past for secured effective been claims over each Our XX% by billing the begin population, and has and covered reimbursement XX will also will January puzzle which will to determination, date, the front become reimbursement our and that payment which paying of submitting is Medicare. we coverage the of of final on
also payers beginning half for to these of private XXXX. start coverage hope process securing first in are the payments We and the and
EsoCheck to in products Mark launch submit we to noted, approval and mid-XXXX. CE completed in Mark would EsoGuard necessary CE allow in This audit have Europe As these us for certifications Europe self-certification. the pursue and
noted, shutdown the following BE-X On clinical a EsoGuard track trials, to X clinical previously front, complete COVID-XX. international of two our and trial are clinical as due research back near on multicenter
other trials to If patients slowdown. GERD of high-risk control study you disease. case study in or non-research future recall, although FDA activity, vulnerable winter the patients screening these is unlike an COVID-XX trials known for is research a PMA In-Vitro does IVD. and is clinical submission One and support remain as these accelerating with of Enrollment clinical EsoGuard/EsoCheck a a Diagnostic registration of
the across to U.S. we to back; Despite active of hold assuming enrollment coming in XXXX active the doesn’t slowdowns, sites quarter. XX our XX studies. these sites nine European have us pandemic the and U.S. the enrolled an additional We two complete in patients steps, we’re end sites XX target have maintaining expect
today. with data EsoGuard result encouraging the of very we have have acceptance over the patient not results trial, received performance Although procedure we XX% end received very will EsoCheck until satisfaction. user The positive
Let me in some now developments division. briefly Health our summarize additional GI
uses disposable ablate Device, Once We’re progress patented esophageal and our balloon ablation making is EsoCure single-use thermal call our catheter, a EsoCure Esophageal Technology which to excellent detect on cleared tissue. Ablation Caldus we from and the for before allow complex do it commercialized, treat to capital and without technologies and to equipment cancer, others. BE dysplastic so to expensive can progress by Medtronic EsoCure clinicians would need current on
to has completed submission proceed targeted testing with trial, And of Pennsylvania note EsoCheck another common, soon a the the requires for and of expect We pilot prototype patients XXXX. exploring but or University animal which treatment that enrollment with FDA the eosinophilic treatment. multiple very EOE. invasive of course of a monitoring endoscopies condition, with EOE currently is role in during underappreciated allergy-mediated in esophogitis
the Seattle, from role various at trial Fred this and of could of EsoCheck to non-dysplastic due explore continue detect of the designed partners trial, their in to to Our beards, dysplastic greatly hold patients. Cancer facilitate the Hutch Center to which surveillance progression biomarkers we’ll COVID,
prior exclusive this treated of these prove effective if trial. license clinical to development biomarkers to can be secured So, option the cancer. in the We they they
move CarpX patented The which disposable, scarred the pushing designed and treat invasive let’s tensioning away. Minimally catheter minimally When under activated, device bipolar Health carpal balloon inserted reducing cut includes precisely our ligament, from to ligament device matter radiofrequency stock is while tendons GI while inside the estimated is it carpal recovery seconds. the nerve Now, the from Interventions, $X Invasive to recovery time. electrodes will the after to tunnel chain CarpX marketing dramatically addressing this single-use, syndrome late XXX(k) domestic believe COVID-XX-related times were year, was targeting a market addressable supply August. FDA and compared clearance opportunity. immediately in issue, commission able reduce traditional of to in U.S. tunnel earlier billion secure we out granted CarpX release, inventory in an We CarpX.
and CarpX EsoCheck for interventional steady unlike procedure, strategy deliberate procedure. CarpX the an commercial Our procedure the remains as
a invasive Although training technical require which tunnel significantly than comes it carpal traditional and does with less skill, release, partner.
of marketing device who first interventional in ambassadors, core training, step establish the participate evangelizing can any before other critical well-trained technology, to with to a hand As group is widely to surgeons. with surgeons and proctoring surgeon
a such of surgeons, We team Board. serve hand our secured on Advisory are world-class who CarpX now
U.S. week the week. The training first our coming me, cadaver was excuse completed in successfully first commercial we forward to session and look cadaver testing, procedures last the
estimated Next, allows with some based bone current with our addressing highlights our device, medications, PortIO direct patients access those poor is division, from renal be to fluids, $XXX vain an and the intraosseous brief veins Therapy and opportunity to which access failure, NextFlo. marrow other must and includes which implantable, preserved substances, million deliver Infusion PortIO hemodialysis. whose market on carefully for or future vascular
short-term IDE to are an to our de clinical and limitations our FDA COVID-XX proposed team investigational enrollment with on we novo very through lifted restrictions. have hold We due have final discussions initiating study our FDA’s The device next is seeking application. current with These exemption activity this early the on the and to focused initiate restrictions in been or initial pathway. well has visits implant to States support America Columbia, travel indication month travel approval the site United These duration progressed in to related hope or PortIO on discussions goal early next in been now the of study XXXX. have year. will South Columbia long-term IDE and
the IV and infusions, since most which million pumps delivers bag one of of height delivered the eliminate for the the next Our expensive system, to of infusion highly in States driven infusion accurate complex independent intravenous infusions the need gravity slow then. United estimated for seeks electronic
electronic going infusion the advance work physician approaching development pumps. testing. through to and is accuracy system launch with rates of well extremely full intravenous expensive flow This continue next and We design
technology our to infusion once to used FDA the expect commercial next proceed several our in XXX(k) cleared, in are license economics to These plan their of early centers, We perform deep NextFlo infusion consummate which don’t in in working are submission at launch to we ambulatory large pumps. an year. the to discussions again, we active relative few our medical targeted laboratory. setting care testing process partners to innovations Once deep We health focusing we’re a division their complete this technologies but are the time disposable We with a cover of a electronic process, own their diligence remain here with technology have strategic partners M&A own transaction. beginning pumps, exciting on for and in outpatients. highlights. other for on projects enough emerging including hope much,
year. for each undergo who tube manufactured pediatric aqueous proprietary technology one the the silk children, ear million resorbable seek DisappEAR of placement tubes bilateral Our to my estimated revolutionize care
manufacturer technology global work schedule. proceeding and We is are ahead Virginia. in fully partnered with That Inc.'s manufacturing Canon now U.S. center of
also on recently plan R&D progressing for well. we’ll reinitiate to also ready We received is as in signal-to-noise and the prototype license that them. second diabetic Those to several our ear front. molded commercial testing, bench early-stage model. areas ECMO the initiate be with prototype developed dramatically including Solys for non-invasive I’ll cardiopulmonary team a volunteers testing animal Dennis grade, McGrath. allow fibroin generation technologies, ratio, of agreement. accurate in results us blood we’ll our have NDIR a initial that top defined which testing should in rat aqueous mechanical working support – silk, laser-based now innovation We our of emerging in which ventilation. human monitoring on pass achieve milestone – exciting improved technology were tubes animal to is a We sufficiently and completed first-generation recently glucose it
